This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)

Tipranks - Tipranks - Thu May 21, 5:32AM CDT

J.P. Morgan analyst maintained a Buy rating on United Therapeutics today and set a price target of $685.00.

Meet Samuel – Your Personal Investing Prophet

In addition to J.P. Morgan, United Therapeutics also received a Buy from Jefferies’s Roger Song in a report issued yesterday. However, on May 11, Oppenheimer assigned a Hold rating to United Therapeutics (NASDAQ: UTHR).

See the top stocks recommended by analysts >>

Based on United Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $781.5 million and a net profit of $274.9 million. In comparison, last year the company earned a revenue of $794.4 million and had a net profit of $322.2 million

Based on the recent corporate insider activity of 393 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year. Earlier this month, Nilda Mesa, a Director at UTHR sold 258.00 shares for a total of $150,137.94.

Read More on UTHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).